Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
Postgraduate Institute of Medical Sciences (SGPGIMS); Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER); The Lundquist Institute and Harbor-UCLA Medical Center; The Dudley Group NHS Foundation Trust; University of Birmingham.Publication date
01/03/2023Subject
Cardiology
Metadata
Show full item recordAbstract
The present review summarizes the burden, risk factors, biomarkers of and therapeutic consideration for cardiovascular disease in systemic vasculitis. Ischemic heart disease (IHD) and stroke are intrinsic features of Kawasaki disease, Takayasu arteritis, Giant Cell Arteritis (GCA), and Behcet's disease. The risk of IHD and stroke is increased in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and cryoglobulinemic vasculitis. Behcet's disease could present with venous thromboembolism. The risk of venous thromboembolism is increased in AAV, polyarteritis nodosa, and GCA. The risk of cardiovascular events is greatest at or immediately after the diagnosis of AAV or GCA, therefore, controlling vasculitis disease activity is of utmost importance. Traditional as well as disease-related risk factors drive the heightened cardiovascular risk in vasculitis. Aspirin or statins reduce the risk of IHD or stroke in GCA or the risk of IHD in Kawasaki Disease. Venous thromboembolism in Behcet's disease should be treated with immunosuppressive therapy rather than with anticoagulation. Competing Interests: Declaration of competing interest None of the authors have any conflicts of interest to declare. Copyright 2023 Elsevier Ltd. All rights reserved.Citation
Misra DP, Sharma A, Karpouzas GA, Kitas GD. Cardiovascular risk in vasculitis. Best Pract Res Clin Rheumatol. 2023 Mar;37(1):101831. doi: 10.1016/j.berh.2023.101831. Epub 2023 Jun 9. PMID: 37302927.Type
ArticlePMID
37302927Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.berh.2023.101831